Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-BCAT · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Monotherapy: Dose Escalation | EXPERIMENTAL | Patients will be administered multiple doses of ALN-BCAT. |
| Monotherapy: Dose Expansion | EXPERIMENTAL | Patients will be administered multiple doses of ALN-BCAT. |
| Combination Therapy: Dose Escalation | EXPERIMENTAL | Patients will be administered multiple doses of ALN-BCAT in combination with pembrolizumab. |
| Combination Therapy: Dose Expansion | EXPERIMENTAL | Patients will be administered multiple doses of ALN-BCAT in combination with pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| ALN-BCAT | DRUG | Administered by intravenous (IV) infusion |
| Pembrolizumab | DRUG | Administered by intravenous (IV) infusion |
Inclusion Criteria: * Has HCC confirmed histologically or cytologically, or, for patients with liver cirrhosis, clinically by the American Association for the Study of Liver Diseases (AASLD) criteria * Has had at least one line of systemic therapy for unresectable advanced or metastatic disease * H...
ALN-BCAT is an investigational drug being developed for the treatment of advanced hepatocellular carcinoma, a type of liver cancer. It is also being studied in patients with metastatic hepatocellular carcinoma. The drug is currently in Phase 1 clinical development and has not yet been approved by regulatory authorities.
ALN-BCAT is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALNY. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of ALN-BCAT in patients with advanced hepatocellular carcinoma.
ALN-BCAT is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants to evaluate the drug's safety, tolerability, and preliminary efficacy in patients with advanced hepatocellular carcinoma.
ALN-BCAT is being evaluated in a Phase 1 clinical trial with the identifier NCT06600321, titled 'A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma.' This trial is currently recruiting participants and aims to enroll approximately 158 patients with advanced or metastatic hepatocellular carcinoma across the United States, Italy, and South Korea.
ALN-BCAT is the primary name for this investigational drug candidate. No alternative names have been reported for this compound. It is being developed by Alnylam Pharmaceuticals and is currently in Phase 1 clinical trials for the treatment of advanced hepatocellular carcinoma.